AUTHORS
Jongwon Yoon, PhD, Jie Ern Sim2, Matthew Shaw, PhD3, Kwee Yong, Prof4, Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath(Haem), PhD5, Paul Maciocia6
AFFILIATIONS
1 University College London, London, United Kingdom
2 University College London, London, United Kingdom
3 University College London, London, United Kingdom
4 University College London, London, United Kingdom
5 University College London, London, United Kingdom
6 University College London, London, United Kingdom
ABSTRACT
Background:
Relapse after CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukaemia is frequently driven by loss of functional persistence. Most persistence screens use in vitro systems, immunodeficient mice or loss-of-function designs, which can miss clinically useful gain-of-function regulators selected under intact host immune pressure. Here, we developed a targeted syngeneic CRISPR activation screen to identify transcription factors that can be co-expressed with a CAR to improve persistence.
Methods:
Splenocytes from dCas9-SAM mice were transduced with an mCD19.28z CAR and a CRISPR activation library targeting 1,607 murine transcription factors, then transferred into B6.SJL-CD45.1 mice bearing E2a-PBX1 B-ALL. sgRNA enrichment was measured in CAR T cells recovered 4 to 8 weeks after engraftment.
Results:
The in vivo screen identified OCT2 (POU2F2), a canonical B-cell transcription factor with no established role in T-cell biology, as one of the strongest drivers of long-term CAR T-cell persistence. To test this in human cells, we generated CD19.28z CAR T cells stably co-expressing human OCT2. Under repetitive NALM6 stimulation, OCT2-expressing CAR T cells showed a marked advantage over control CAR T cells, with superior survival and sustained anti-tumour activity across serial challenge, while preserving short-term killing in co-culture. This was not limited to CD28 costimulation: OCT2 produced the same persistence advantage in CD19.41BBz CAR T cells, supporting a transferable effect across CAR architectures. Crucially, OCT2 CAR T cells retained comparable tumour killing while producing slightly less cytokine and adopting a less activated profile, a combination consistent with improved functional fitness rather than nonspecific activation. After repeated tumour challenge, transcriptomic profiling showed that OCT2-expressing CAR T cells were driven toward a progenitor-exhausted, stem-like state, with increased expression of TCF7, BCL6, BACH2, SELL and SLAMF6, together with repression of the terminal exhaustion regulator TOX. The in vivo effect was also strong. In NALM6-bearing NSG mice, CD19.28z.OCT2 CAR T cells improved overall survival and achieved prolonged systemic persistence compared with control CAR T cells. After tumour rechallenge, OCT2-expressing CAR T cells retained tumour control, showing that OCT2 preserves functional competence under pressure. The clinical relevance of this programme was supported by independent single-cell datasets from paediatric and adult CD19 CAR T-cell recipients, where the OCT2 regulon was enriched in long-term persisting CAR T-cell clones from responders.
Conclusion:
These data identify OCT2 as a cross-lineage transcriptional regulator that gives CAR T cells a more durable, less overactivated functional state. The phenotype is consistent across serial stimulation, CD28z and 41BBz CAR formats, in vivo persistence, survival and tumour rechallenge, supporting OCT2 as a high-priority engineering module for improving CAR T-cell durability without sacrificing cytotoxic function.
DISCLOSURES
Jongwon Yoon, PhD: No relevant conflicts of interest to declare.